-
Nautilus Biotechnology (NAUT) PT Lowered to $2.50 at Guggenheim
-
Goldman Sachs Downgrades Nautilus Biotechnology (NAUT) to Sell
-
Nautilus Biotechnology, Inc. (NAUT) Tops Q3 EPS by 4c
-
Nautilus Biotechnology, Inc. (NAUT) Tops Q2 EPS by 2c
-
Guggenheim Starts Nautilus Biotechnology (NAUT) at Buy

